In phase 3 trials and real-world settings, lower proportions of patients with genotype 3 hepatitis C virus (HCV) infection and cirrhosis have a sustained virologic response 12 weeks after treatment (SVR12) with the combination of sofosbuvir and velpatasvir than patients without cirrhosis. It unclear whether adding ribavirin to this treatment regimen increases SVRs among patients with genotype 3 HCV infection and cirrhosis.